Mirati Therapeutics Inc. (MRTX) is owned by a number of high-value investors. Its largest direct holder is Charles M. Baum President, Chief Executive Officer and Director with 66,599 shares. The second-largest direct holder is Aaron I. Davis Director, with 37,052 shares of the company’s stock. In third place with 35,836 shares of MRTX is Isan Chen Executive Vice President and Chief Medical and Development Officer.
Now turning to institutional ownership of Mirati Therapeutics Inc. (MRTX), Tavistock Life Sciences Co. (Investment Management) is the top holder with 5.0 million shares. The next largest fund holder of this company’s stock is Avoro Capital Advisor LLC with 3.0 million shares. In the third-place spot with 2.0 million shares is The Vanguard Group, Inc..
This company’s stock price was $94.89 at the previous market close, with its latest volume reaching 1064548. Compare that to its average daily volume of 672.89K. Given the fact that this stock has 39.30M shares outstanding, its current market value is sitting at $3.73B. This publicly-traded stock’s 60-month Beta is 2.03. Its Price to Sales ratio is 703.62, its Price to Cash Flow ratio is 7.68, and its Price to Book ratio is 7.27.
MRTX stock has achieved a 5-day range of $75.39 to $99.99, with a total performance of +21.11% during that period. Meanwhile, in the past month of trading, this stock has traded in the range of $69.50 to $99.99, generating a +21.79% change during the period. In the past three months, this stock’s price has changed by -4.15%, trading in the range of $69.50 to $111.99.
In the past 5 days, shares of MRTX have made a new high 4 times. In the last month, it has made a new high 5 times, and in the past 3 months, it has made a new high 1 time.
Now let’s turn to this public company’s earnings. For the quarter ending 6/29/2019, the earnings per share (EPS) was reported at -1.26. This is a -0.06 difference compared to the consensus estimate of -1.2, amounting to an earnings surprise of -5.00%. In the previous quarter, which ended in 6/29/2019, the consensus estimate was -0.97, making for an earnings surprise of -20.60%. For the quarter ending 12/30/2018, EPS was reported at -0.87, generating a 0.00% earnings surprise.
The Net Income for the most recent full fiscal year, which ended in 12-2018, was $-98.0 million. This is compared to the prior year, where Net Income was $-70.0 million. Meanwhile, this company’s Operating Cash Flow was $-70.0 million for the year, compared to $-64.0 million in 2017. Capital Expenditures for the year were reportedly $122000, compared to $81000, and Free Cash flow was $-70.0 million compared to the prior year’s $-64.0 million.
Mirati Therapeutics Inc. (MRTX) stock currently has a Financial Strength score of 10/10. This is due to a combination of factors, including a Cash to Debt ratio of No Debt, an Equity to Asset ratio of 0.94. The Interest Coverage of this stock is No Debt, its Piotroski F-Score is 4, its Altman Z-Score is 64.17 and its Beneish M-Score is -2.99.
This publicly-traded company’s Profitability and Growth score is 2/10, thanks to a combination of things: an Operating Margin of -2822.16, a Net Margin of -2692.01, a ROE of -49.73, and a ROC of -33575.94.
Shifting focus now to Valuation and Return for MRTX, this company’s Price to Tangible Book is 7.27 and its Price to Median PS Value is 4.63. Price to Peter Lynch Fair Value for MRTX is now 0.00.
Certain ratios provide helpful insights into how a stock is performing. The Quick Ratio for MRTX is sitting at 17.57, while its Current Ratio is 17.57. This stock’s PB Ratio is 7.24, its PS Ratio is 600.56.